Evidence map›Paper›PMID 40274132›Full record

ArticleNeurobiology of disease2025

Oligodendrocyte myelin glycoprotein impairs dendritic arbors via schizophrenia risk gene Trio.

Euan Parnell, Jessica M Christiansen, Michelle A Spratt, Shelby Ruiz, Matthew L Macdonald, Peter Penzes, Robert A Sweet, Melanie J Grubisha

Abstract read
In one paragraph

Article in Neurobiology of disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Phosphatase Signaling as a Therapeutic Strategy in Schizophrenia.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Euan ParnellDepartment of Neuroscience, Northwestern University Feinberg School of Medicine, Chicago, IL 6061, United States of America.
Jessica M ChristiansenDepartment of Neuroscience, Northwestern University Feinberg School of Medicine, Chicago, IL 6061, United States of America.
Michelle A SprattDepartment of Psychiatry, Translational Neuroscience Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States of America.
Shelby RuizDepartment of Psychiatry, Translational Neuroscience Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States of America.
Matthew L MacdonaldDepartment of Psychiatry, Translational Neuroscience Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States of America.
Peter PenzesDepartment of Neuroscience, Northwestern University Feinberg School of Medicine, Chicago, IL 6061, United States of America; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States of America; Centre for Autism and Neurodevelopment, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Robert A SweetDepartment of Psychiatry, Translational Neuroscience Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States of America; Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States of America.
Melanie J GrubishaDepartment of Psychiatry, Translational Neuroscience Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States of America. Electronic address: grubisham@upmc.edu.

Funding

Structural determinants and pharmacological modulation of synaptic GEFs and GAPsP50MH132775 · NIMH · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Peter Penzes · 2024 to 2026
$12.9M
Small GTPase signaling in spinesR01MH071316 · NIMH · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BARBOLINA, MARIA V., PENZES, PETER · 2005 to 2025
$7.1M
Plasticity of Auditory Cortical Circuits in SchizophreniaR01MH071533 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWEET, ROBERT A · 2004 to 2018
$6.9M
Synaptic Resilience to Psychosis in Alzheimer DiseaseR01MH116046 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Julia K Kofler, ROBERT A SWEET · 2018 to 2026
$6.6M
Fine-Mapping Genome-Wide Associated Loci using Multi-omics Data to Identify Mechanisms Affecting Serious Mental IllnessR01MH125235 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEVLIN, BERNIE, MACDONALD, MATTHEW L · 2021 to 2024
$3.0M
Targeting Postsynaptic Small G-protein RegulatorsR01MH130838 · NIMH · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LUAN, CHI-HAO, PENZES, PETER · 2022 to 2025
$2.7M
Synaptic Protein Networks, Genetic Risk, and Spine Loss in SchizophreniaR01MH118497 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MACDONALD, MATTHEW L · 2019 to 2023
$2.5M
Providing New Insight Into Adolescent Dendritic DevelopmentR01MH132586 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Melanie Jean Grubisha · 2024 to 2026
$1.7M
Enhanced NGR/p75/KAL9 Signaling and Impaired Dendritic Morphogenesis in Schizophrenia - SupplementK08MH118513 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GRUBISHA, MELANIE JEAN · 2019 to 2023
$805k
NIMH NIH HHS K08 MH118513NIMH NIH HHS P50 MH132775NIMH NIH HHS R01 MH071316NIMH NIH HHS R01 MH071533NIMH NIH HHS R01 MH116046NIMH NIH HHS R01 MH118497NIMH NIH HHS R01 MH125235NIMH NIH HHS R01 MH130838NIMH NIH HHS R01 MH132586
6 · The paper itself

Abstract

During adolescence, a critical developmental epoch coincident with the emergence of clinical symptoms of schizophrenia, cerebral cortical dendritic growth shifts from a rapid phase, reaching equilibrium. Oligodendrocyte Myelin Glycoprotein (OMGp) expression peaks during adolescence and has a known role in regulating dendritic stabilization. However, the precise signaling pathways transduced by OMGp are unknown. To identify these pathways, we performed unbiased phospho-proteomic analysis after OMGp stimulation, revealing 2991 phosphorylated proteins. Interestingly, several schizophrenia risk genes were identified as phospho-targets, including the potent risk factor Trio, which has a known role in regulating neurite outgrowth and the cytoskeleton through its dual Rac/RhoA catalytic domains. Phosphomimetic and phosphonull Trio9 constructs were employed to assess the functional role of OMGp-mediated phosphorylation at a novel phosphosite - Ser1258. Phosphomimetic Trio9 was deficient in Rac1 catalytic activity and induced loss of dendritic length and complexity compared to wild type protein. Moreover, phosphonull constructs blocked the OMGp-induced impairments in dendritic length and complexity. Together, these results highlight the ability of OMGp to regulate dendritic architecture by potently inhibiting the Rac1 catalytic activity of Trio through phosphorylation. These results provide a potential mechanism contributing to the emergence of neuronal structural dysfunction and schizophrenia symptomology during adolescence.

Indexed as

DendritesMyelin-Oligodendrocyte GlycoproteinSchizophreniaAnimalsHumansPhosphorylationrac1 GTP-Binding ProteinRatsMyelin-Oligodendrocyte Glycoproteinrac1 GTP-Binding ProteinDevelopmentOMGpPhosphoproteomicsSchizophreniaTrioTriple functional protein

Identifiers

PMID40274132
PMCPMC12180307

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.